• Nenhum resultado encontrado

Rev. Assoc. Med. Bras. vol.59 número3

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Assoc. Med. Bras. vol.59 número3"

Copied!
1
0
0

Texto

(1)

r e v a s s o c m e d b r a s .2 0 1 3;5 9(3):217

Revista da

ASSOCIAÇÃO MÉDICA BRASILEIRA

w w w . r a m b . o r g . b r

Correspondence

Postmenopausal osteoporosis, breast cancer, and aromatase

inhibitor

Osteoporose pós-menopausa, câncer de mama e o inibidor

da aromatase

Dear Editor,

The recent article on bone mineral density in postmenopausal women with and without breast cancer was very interest-ing. Conde et al. concluded that The prevalence of abnormal bone mineral density (BMD) was higher in postmenopausal breast cancer survivors (BCS) than in postmenopausal women without breast cancer”.1 Certainly, the concern regarding

osteoporosis in the cancerous patient is very important. As Conde et al. mentioned, “special vigilance and the adoption of interventions should be instituted early to minimize bone loss”. Indeed, cancer therapy should also be focused on mon-itoring osteoporosis among cancerous patients. The use of aromatase inhibitor as an adjuvant therapy in breast can-cer is quite intriguing.2It was recently reported that the use

of aromatase inhibitor significantly increased osteoporosis, especially at femur region.2

Conflicts of interest

The authors declare no conflicts of interest.

r e f e r e n c e s

1. Conde DM, Costa-Paiva L, Martinez EZ, Pinto-Neto AM. Bone mineral density in postmenopausal women with and without breast cancer. Rev Assoc Med Bras. 2012;58(6):673–8.

2. Mutlu H, Aslan T, Yılmaz GS, Erden A, Cihan YB, Akca Z, et al. Osteoporosis associated with aromatase inhibitors is different from post-menopausal osteoporosis. Adv Lab Med Int. 2013;3(1):1–5.

Somsri Wiwanitkita,∗, Viroj Wiwanitkitb

aWiwanitkit House, Bangkhae, Bangkok, Thailand

bHainan Medical University, China, Faculty of Medicine, University of Nis, Serbia, Joseph Ayobabalola University, Nigeria

Corresponding author:Wiwanitkit House, Bangkhae, Bangkok Thailand 10160.

E-mail: somsriwiwan@hotmail.com (S. Wiwanitkit).

0104-4230/$ – see front matter

Referências

Documentos relacionados

In the North, cervical cancer mortality was higher than that of breast cancer throughout the period, and there was a fall in deaths among women living in the state capitals and

The study indi- cates that survivors of breast cancer had a be er quality of life compared to women without the

Breast cancer and hormone replacement therapy: colaborative reanalysis of data from 51 epidemiological studies of 52705 women without breast cancer and 108411 women with breast

From these results, the authors concluded that risk of breast cancer among HT users was higher in those using the combined estrogen-progestin therapy than in those who

Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY

with risk of postmenopausal breast cancer in the Iowa women’s health study. Cancer Epidemiol

The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Prospective

Aim - To study a possible relationship between chronic gastritis, parietal cell density of the oxyntic mucosa and bone mineral density in postmenopausal women, as chronic